Fatty acid synthase (FASN) levels in serum of colorectal cancer patients: correlation with clinical outcomes

被引:40
作者
Long, Qi-qiang [1 ,2 ]
Yi, Yong-xiang [3 ]
Qiu, Jie [2 ]
Xu, Chuan-jun [4 ]
Huang, Pei-lin [1 ]
机构
[1] Southeast Univ, Sch Med, Dept Internal Med, Nanjing 210009, Peoples R China
[2] Southeast Univ, Affiliated Hosp 2, Dept Internal Med, Nanjing 210003, Peoples R China
[3] Southeast Univ, Affiliated Hosp 2, Dept Surg Med, Nanjing 210003, Peoples R China
[4] Southeast Univ, Affiliated Hosp 2, Dept Med Imaging, Nanjing 210003, Peoples R China
基金
中国国家自然科学基金;
关键词
Fatty acid synthase (FASN); Colorectal cancer; Enzyme-linked immunosorbent assay (ELISA); EXPRESSION; INHIBITION; ACTIVATION;
D O I
10.1007/s13277-013-1510-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Fatty acid synthase (FASN) is a common phenotype to many kinds of human cancers, such as those of the breast, ovary, pancreas, prostate, colon, and so on. Increased FASN levels have been detected in the serum of the patients with breast and pancreatic cancers. The relationship between the FASN level in serum and the clinicopathological characteristics of colorectal cancer is investigated in this study. FASN levels in serum were examined with enzyme-linked immunosorbent assay (ELISA) in 74 patients with colorectal cancer and 40 healthy persons. Pathological and clinical factors associated with FASN concentrations in serum were investigated and analyzed by statistical analysis. The FASN level in colorectal cancer patients' serum is significantly higher than that in healthy persons' serum. FASN levels in the serum of colorectal cancer patients are associated with tumor extent, lymph node metabasis status, distant metastasis, and tumor clinical stage. The 5-year overall survival rate and 5-year disease-free survival rate among patients with low FASN levels in serum are significantly higher than those among patients with high FASN levels in serum (log-rank P = 0.003). The high FASN level in serum is a promising independent predictor of colorectal cancers with advanced phases, late clinical stages, and shorter survival. These results suggest that FASN concentration in serum may be a potential and useful tumor marker.
引用
收藏
页码:3855 / 3859
页数:5
相关论文
共 26 条
[1]   Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice [J].
Alli, PM ;
Pinn, ML ;
Jaffee, EM ;
McFadden, JM ;
Kuhajda, FP .
ONCOGENE, 2005, 24 (01) :39-46
[2]  
Alo PL, 1996, CANCER, V77, P474, DOI 10.1002/(SICI)1097-0142(19960201)77:3<474::AID-CNCR8>3.0.CO
[3]  
2-K
[4]   Fatty acid synthase: A metabolic oncogene in prostate cancer? [J].
Baron, A ;
Migita, T ;
Tang, D ;
Loda, M .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2004, 91 (01) :47-53
[5]   Fatty acid synthase over expression is an indicator of tumor aggressiveness and poor prognosis in renal cell carcinoma [J].
Horiguchi, Akio ;
Asano, Tomohiko ;
Asano, Takako ;
Ito, Keiichi ;
Sumitomo, Maikoto ;
Hayakawa, Masamichi .
JOURNAL OF UROLOGY, 2008, 180 (03) :1137-1140
[6]   EGCG inhibits protein synthesis, lipogenesis, and cell cycle progression through activation of AMPK in p53 positive and negative human hepatoma cells [J].
Huang, Chi-Hung ;
Tsai, Shang-Jie ;
Wang, Ying-Jan ;
Pan, Min-Hsiung ;
Kao, Jung-Yie ;
Way, Tzong-Der .
MOLECULAR NUTRITION & FOOD RESEARCH, 2009, 53 (09) :1156-1165
[7]  
Huang PL, 2000, WORLD J GASTROENTERO, V6, P295
[8]   THE PROGNOSTIC VALUE OF ONCOGENIC ANTIGEN-519 (OA-519) EXPRESSION AND PROLIFERATIVE ACTIVITY DETECTIVE BY ANTIBODY MIB-1 IN NODE-NEGATIVE BREAST-CANCER [J].
JENSEN, V ;
LADEKARL, M ;
HOLMNIELSEN, P ;
MELSEN, F ;
SOERENSEN, FB .
JOURNAL OF PATHOLOGY, 1995, 176 (04) :343-352
[9]  
Kridel SJ, 2004, CANCER RES, V64, P2070, DOI 10.1158/0008-5472.CAN-03-3645
[10]   Fatty acid synthase and cancer: New application of an old pathway [J].
Kuhajda, FP .
CANCER RESEARCH, 2006, 66 (12) :5977-5980